anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Polymers comprising a polymeric backbone and an ion channel modulating compound are described. The ion channel modulating compounds may be aminocyclohexyl ether compounds. Pharmaceutical compositions containing the polymers and therapeutic uses thereof are also described. Also provided are ring opening metathesis polymerization processes for the preparation of the polymers including polymers comprising aminocyclohexyl ether ion channel modulating compounds. ROMP polymerization of ROMP active monomers, such as cyclic olefins (e.g. norbornene or 7-oxanorborne or derivatives of, e.g. 7-oxa-bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid) that are attached via a linker to ion channel modulating compounds provide for high loading polymeric drug delivery systems.
BACKGROUND: One of the challenges in surgery of tumors in motor eloquent areas is the individual risk assessment for postoperative motor disorder. Previously a regression model was developed that permits estimation of the risk prior to surgery based on topographical and neurophysiological data derived from investigation with nTMS (navigated Transcranial Magnetic Stimulation). This study aims to analyze the impact of including additional neurophysiological TMS parameters into the established risk stratification model for motor outcome after brain tumor surgery.
METHODS: Biometric and clinical data of 170 patients with glioma in motor eloquent areas were collected prospectively. In addition, the following nTMS parameters were collected bihemispherically prior to surgery: resting motor threshold (RMT), recruitment curve (RC), cortical silent period (CSP) and a nTMS based fibertracking to measure the tumor tract distance (TTD). Motor function was quantified by Medical Research Council Scale (MRCS) preoperatively, seven days and three months postoperatively. Association between nTMS parameters and postoperative motor outcome was investigated in bivariate and multivariable analyses.
RESULTS: The bivariate analysis confirmed the association of RMT ratio with the postoperative motor outcome after seven days with higher rates of worsening in patients with RMT ratio > 1.1 compared to patients with RMT ratio ≤ 1.1 (31.6% vs. 15.1%, p = 0.009). Similarly, an association between a pathological CSP ratio and a higher risk of new postoperative motor deficits after seven days was observed (35.3% vs. 16.7% worsening, p = 0.025). A pathological RC Ratio was associated postoperative deterioration of motor function after three months (42.9% vs. 16.2% worsening, p = 0.004). In multiple regression analysis, none of these associations were statistically robust.
CONCLUSIONS: The current results suggest that the RC ratio, CSP ratio and RMT ratio individually are sensitive markers associated with the motor outcome 7 days and 3 months after tumor resection in a presumed motor eloquent location. They can therefore supply valuable information during preoperative risk-benefit-balancing. However, underlying neurophysiological mechanisms might be too similar to make the parameters meaningful in a combined model.
ETHNOPHARMACOLOGICAL RELEVANCE: Novel drugs are needed to address the issue of malarial infection resistance; natural items can be a different source of these medications. Albizia malacophylla (A. Rich.) Walp. (Leguminosae) is listed as one of the antimalarial medicinal plants in Ethiopian folk medicine. However, there are no reports regarding the biological activity or phytochemistry of the plant.
AIM OF THE STUDY: Thus, this study aimed to evaluate the A. malacophylla crude extract and solvent fractions' in vivo antimalarial activity utilizing 4-day suppressive, preventative, and curative tests in mice infected with P. berghei.
MATERIALS AND METHODS: The parasite Plasmodium berghei, which causes rodent malaria, was used to infect healthy male Swiss Albino mice, weighing 23-28 g and aged 6-8 weeks. Solvent fractions such as methanol, water, and chloroform were given in addition to an 80% methanolic extract at 100, 200, and 400 mg/kg doses. A Conventional test such as parasitemia, survival time, body weight, temperature, and packed cell capacity were employed to ascertain factors such as the suppressive, curative, and preventive tests.
RESULTS: Every test substance dramatically reduced the number of parasites in every experiment. Crude extract (with the highest percentage suppression of 67.78%) performs better antimalarial effect than the methanol fraction, which is the most efficient solvent fraction with a percentage suppression of 55.74%. With a suppression value of 64.83% parasitemia level, the therapeutic effects of 80% methanolic crude extract were greater than its curative and preventative effects in a four-day suppressive test. The survival period (17 days) was longer with the hydroalcoholic crude extract dose of 400 mg/kg than with other doses of the materials under investigation.
CONCLUSIONS: The results of this investigation validate the antimalarial characteristics of A. malacophylla leaf extract. The crude extract prevented weight loss, a decline in temperature, and a reduction in PCV. The results demonstrate that the plant has a promising antimalarial effect against P. berghei, hence supporting the traditional use of the plant. Therefore, it could serve as a foundation for the development of new antimalarial drugs.
The time course of anti-FXa activity following ANDEXXA administration was consistent among the healthy volunteer studies and the ANNEXA-4 study in bleeding subjects [see Clinical Studies (14)]. Compared to baseline, there was a rapid and substantial decrease in anti-FXa activity corresponding to the ANDEXXA bolus. This decrease was sustained through the end of the ANDEXXA continuous infusion. The anti-FXa activity returned to the placebo levels approximately two hours after completion of a bolus or continuous infusion. Subsequently, the anti-FXa activity decreased at a rate similar to the clearance of the FXa inhibitors.

Seventy-one subjects were anticoagulated with apixaban and had baseline levels of anti-FXa activity > 150 ng/mL. Nineteen subjects who were anticoagulated with rivaroxaban had elevated baseline anti-FXa activity levels >300 ng/mL. Forty-eight of the 71 apixaban-treated subjects (68%) experienced a > 90% decrease from baseline anti-FXa activity after administration of ANDEXXA. Ten of the 19 rivaroxaban subjects (53%) experienced a > 90% decrease from baseline anti-FXa activity after administration of ANDEXXA.
In osteoporosis, skeletal bone mass and strength are so reduced that fractures occur after only modest levels of mechanical stress that would not harm normal bone. Fractures of the hip, spine, and wrists are most typical, though fractures of the ribs, pelvis, and humerus also occur. Research has shown that hip fractures cause a 10% to 20% increase in mortality, and the cost of all osteoporotic fractures is estimated to be $6.14 billion in health care costs and lost earnings per year. The most common form of osteoporosis is postmenopausal osteoporosis. A reduction in bone mineral density of approximately 1% to 2% per year is observed for the first 3 to 5 years after the onset of menopause, then 0.5% to 1% per year thereafter.

PTH was recently approved by the FDA as a daily treatment for osteoporosis. However, PTH must be self-injected, is very expensive, and has been associated with worrisome side effects. The currently approved formulation of daily PTH self-injections is practical for only a small proportion of people with osteoporosis. A once weekly formulation could significantly decrease cost, difficulty of administration, and risks and side effects associated with daily use of PTH. A once weekly injection by a caregiver would also make PTH accessible to populations for whom daily self-injection may not be practical, such as the very elderly or those in assisted living or nursing homes. This study will evaluate the safety and effectiveness of once weekly PTH dosing for women with osteoporosis.

Women will be randomized to receive either PTH or placebo. Women will self-administer injections daily for 4 weeks, then once weekly for 48 weeks. All women will receive calcium and vitamin D supplements daily. Women will visit the clinic six times over the course of a year and will provide urine and blood samples at each visit. Bone mineral density will be measured at 6 and 12 months.
The invention discloses a coconut and mangnolia health-preserving wine which is prepared from the following raw materials, by weight, 20-30 parts of coconut milk, 100-120 parts of mangnolia, 70-80 parts of rye, 5-6 parts of sea cucumber polypeptide, 7-8 parts of egg, 8-11 parts of roast young pigeon meat, 6-7 parts of shortening, 3-5 parts of spray-dried animal blood cells, 8-9 parts of guava, 5-7 parts of stropharia rugoso-annulata, 6-7 parts of Sparassis crispa,8-10 parts of whitebait sauce, 4-6 parts of Difluorobromobenzene, 2-3 parts of Elaeagnus umbellala Thunb, 2-4 parts of Abelmoschus manihot, 1-2 parts of stevia rebaudiana, 2-3 parts of rhizoma drynariae, 1-2 parts of cynomorium songaricum and 6-7 parts of a nutrition additive. The main materials coconut milk and mangnolia have a refreshing taste and have functions of moistening skin, protecting hair, expelling toxin and maintaining skin beauty. The adopted rye is calcium supplement rye, blood-enriching rye and selenium-rich rye, and has rich nutrients. The auxiliary material sea cucumber polypeptide has efficacy of invigorating brain, developing intelligence and delaying aging. Meanwhile, various Chinese herbal medicines such as rhizoma drynariae and the like are adopted in the invention. The coconut and mangnolia health-preserving wine has effects of tonifying kidney, invigorating blood circulation, relieving pain and promoting reunion of fractured bones if taken for a long time.
Risk Summary

There is no information regarding the presence of ado-trastuzumab emtansine in human milk, the effects on the breastfed infant, or the effects on milk production. DM1, the cytotoxic component of KADCYLA, may cause serious adverse reactions in breastfed infants based on its mechanism of action [see Data]. Advise women not to breastfeed during treatment and for 7 months following the last dose of KADCYLA. 

Data

There were no animal lactation studies conducted with ado-trastuzumab emtansine or the cytotoxic component of KADCYLA (DM1). In lactating cynomolgus monkeys, trastuzumab was present in breast milk at about 0.3% of maternal serum concentrations after pre- (beginning Gestation Day 120) and post-partum (through Post-partum Day 28) doses of 25 mg/kg administered twice weekly (about 7 times the clinical dose of KADCYLA). Infant monkeys with detectable serum levels of trastuzumab did not exhibit any adverse effects on growth or development from birth to 1 month of age.
Each participant will receive a single dose of study intervention, either BAY2701250 or placebo. Study intervention will be administered by means of short time i.v. infusion. Up to 8 dose steps are planned to be investigated for i.v. administration.
PURPOSE:To obtain an immunosuppressant containing suillin as an active component and having low toxicity. CONSTITUTION:This immunosuppressant is composed of suillin expressed by the formula and a pharmaceutically permissible carrier. The suillin is obtained by extracting Suillus bovinus, which is a kind of edible mushroom. Suillin can be formulated as an oral or parenteral preparation. The oral daily dose is 0.01-100mg/kg for an adult and 0.01-60mg/kg for an infant and the parenteral daily dosage is 0.01-100mg/kg. This immunosuppressant exhibits immunosuppressive effect by a single administration but may be administered in combination with a known immunosuppressant such as cyclosporin A, thereby the immunosuppressive effect is synergistically strengthened.
For those randomized to CBIT-E, treatment will be administered according to the standard CBIT manual, which includes psychoeducation, functional assessment/interventions, habit reversal training, relaxation techniques, and a motivational reward program. However, there will be two modifications. CBIT-E will include additional in-session and out of session practice of exercises, called competing response. Treatment will include a screening visit, baseline assessment, 11 weeks (9 sessions) of CBIT-E, a post treatment assessment, and a three-month follow up assessment. Further, starting after session 3, there will be four 15-minute practice periods scheduled each week between sessions. During these practice periods, the child and therapist will meet over Microsoft Teams and the therapist will administer an enhanced reward task.
This is a multi-centre, open label, dose escalation study to assess the safety, tolerability and efficacy of two infusions of CYP-001, in adults who have steroid-resistant GvHD.

Participants will receive standard of care treatment throughout the study, according to local procedures. The first eight participants will be enrolled in Cohort A and receive a CYP-001 dose of 1 million cells per kg, up to a maximum dose of 100 million cells, on Day 0 and Day 7. Subject to a safety review of data from Cohort A, an additional eight participants will be enrolled into Cohort B and receive a CYP-001 dose of 2 million cells/kg, up to a maximum dose of 200 million cells, on Day 0 and Day 7. The primary evaluation period concludes for each participant 100 days after the first dose of CYP-001. Participants will have study visits on Days 0, 3, 7, 14, 21, 28, 60 and 100. Subsequently, participants will enter a long term follow-up period, which concludes 2 years after the first dose of CYP-001.
Participants will receive Treatment Z in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
The present invention provides a method for mineralizing commercially available guided bone regeneration membranes. The method comprises the steps of (a) providing a commercially available guided bone regeneration membrane, (b) applying a mineralizing solution, and (c) microwaving the membrane. The method may further comprise (d) rinsing the membrane in a solution such as distilled water and (e) drying the membrane. The mineralizing solution may be a solution capable of supplying or delivering a mineral such as calcium or zinc. The invention further provides guided bone regeneration membranes made by the methods described. The guided bone regeneration membrane comprises a mineral, such as, for instance calcium or zinc at a weight percent of at least 5%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20% or at least 25% (weight percent) of the membrane. Further, the invention provides methods for enhancing bone regeneration and methods for inhibiting bacterial infection and inflammation.
In the lateral decubitus position, a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA) was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. A total of 40 ml of the prepared solutions were injected bilaterally as 20+20 ml.
Resistance (R) genes were used to recognize pathogen effectors directly or indirectly in plants and activate defense signal pathways. Most of these R proteins consist of a nucleotide-binding adaptor (NB-ARC) domain, a leucine-rich repeat (LRR) domain and some also have a coiled-coil (CC) structure. In this study, we cloned a gene which encodes the CC-NB-ARC-LRR R protein (VqCNL) from Chinese wild grapevine Vitis. quinquangularis accession 'Dan-2'. The transcript of VqCNL was obviously induced by inoculation with Plasmopara viticola and the salicylic acid (SA) treatment. The results of sequence analysis showed that the VqCNL gene contained a CC domain at the N-terminus, along with an NB-ARC and an LRR domain at the C-terminus. We transferred this gene into wildtype Arabidopsis and treated transgenic lines with Hyaloperonospora arabidopsidis (Hpa) and Pseudomonas syringae pv. tomato DC3000 (Pst DC3000); the results demonstrated that VqCNL promotes broad spectrum resistance to pathogens. Furthermore, qPCR analysis displayed that VqCNL may display a significant function in disease resistance via activating SA signaling pathways. In general, these conclusions primarily demonstrated that VqCNL enhances the disease resistance level in plants and contributes to future research of the R gene identification for grape breeding biotechnology.
Ancestrally admixed populations are underrepresented in genetic studies of complex diseases, which are still dominated by European-descent populations. This is relevant not only from a representation standpoint but also because of admixed populations' unique features, including being enriched for rare variants, for which effect sizes are disproportionately larger than common polymorphisms. Furthermore, results from these populations may be generalizable to other populations. The South African Cape Coloured (SACC) population is genetically admixed and has one of the highest prevalences of fetal alcohol spectrum disorders (FASD) worldwide. We profiled its admixture and examined associations between ancestry profiles and FASD outcomes using two longitudinal birth cohorts (N=308 mothers, 280 children) designed to examine effects of prenatal alcohol exposure on development. Participants were genotyped via MEGAex array to capture common and rare variants. Rare variants were overrepresented in our SACC cohorts, with numerous polymorphisms being monomorphic in other reference populations (e.g., ∼30,000 and ∼ 221,000 variants in gnomAD European and Asian populations, respectively). The cohorts showed global African (51 %; Bantu and San); European (26 %; Northern/Western); South Asian (18 %); and East Asian (5 %; largely Southern regions) ancestries. The cohorts exhibited high rates of homozygosity (6 %), with regions of homozygosity harboring more deleterious variants when lying within African local-ancestry genomic segments. Both maternal and child ancestry profiles were associated with higher FASD risk, and maternal and child ancestry-by-prenatal alcohol exposure interaction effects were seen on child cognition. Our findings indicate that the SACC population may be a valuable asset to identify novel disease-associated genetic loci for FASD and other diseases.
<P>PROBLEM TO BE SOLVED: To provide a new diagnostic, prophylactic and therapeutic agent, etc., effective for the diagnosing, preventing and treating cancer or inflammatory diseases and free of any side effects.  <P>SOLUTION: A polypeptide having a specific amino acid sequence and having the function of selectively suppressing the matrix metalloproteinase secretion of biological cells and a polypeptide equivalent in function to the above polypeptide are provided. The diagnostic, prophylactic and therapeutic agent for cancer or inflammatory diseases comprises either one of the above polypeptides as the active ingredient. A polynucleotide having a specific base sequence and exhibiting the function of selectively suppressing the matrix metalloproteinase(MMP) secretion of biological cells by expression in the biological cells and a polynucleotide equivalent in function to the above polynucleotide are provided. The vector for diagnosing, preventing and treating cancer or inflammatory diseases constructed by incorporating either one of the above polynucleotides is also provided.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The use of carbohydrates (I) is claimed as active agents for treating intestinal infections in animals, where (I) is not degradable by enzymes in the digestive tract, is other than lactulose and is selected from oligosaccharides, oligosaccharide derivatives, hydrolyzates of polymeric carbohydrates and their mixtures. An independent claim is also included for animal feedstuffs (specifically dietetic feedstuffs) containing (I). ACTIVITY : Antibacterial; Virucide; Fungicide; Antiparasitic; Antiinflammatory; Antidiarrheic; Analgesic; Antiemetic; Antipyretic. MECHANISM OF ACTION : Improvement of condition of bacterial flora; Prevention of deposition and adhesion of pathogenic bacteria on the intestinal epithelium. Some (I) are fermented by the intestinal flora to give lower fatty acids (especially butyric acid), lactic acid and/or acetic acid, which reduce the pH in the large intestine, promote growth of non-pathogenic bacteria and inhibit growth of pathogenic bacteria. Some (I) inhibit deposition of pathogenic bacteria on the intestinal epithelium or block the fimbriae of pathogenic bacteria to inhibit adhesion to the intestinal epithelium.
The present invention is application of geldanamycin (C-3559) in preparing medicine for treating condyloma acuminata and genital tract infection of herpesvirus. Geldanamycin has no stimulation on medial femoral skin of health calf and can inhibit ox papilloma virus DNA copy and make tumor atrophy, age and reduce. C-3559 has broad spectrum antivirus effect and micromole level antivirus activity on several kinds of DNA and RNA viruses. The 41st extracorporeal passage generation has no geldanamycin resisting HSV-1 virus strain separated, and the 15th HSV-1 GA drug-resisting training generation has the same aciclovir sensitivity as the wild strain. Geldanamycin in no cell toxicity concentration can inhibit the synthesis of HSV-1 DNA specifically. Experiment on mouse shows that geldanamycin can inhibit type-II herpesvirus copy in the effect higher than that of aciclovir.
The purpose of this study was to investigate the effects of an eight-week online video bodyweight resistance training on cognitive function and physical fitness in older adults. A total of 30 older adults was randomly assigned into either an exercise group or a control group. The exercise group participated in the exercise and the control group was required to maintain daily living. Mini mental status examination (MMSE) and senior fit-ness tests (SFT) were measured pre- and post-eight weeks of intervention. Participating in the exercise experienced increases in cognitive functions of attention (p < 0.05) and calculation (p < 0.05), recall (p < 0.05), and repetition (p < 0.05) from the MMSE. Also, older adults in the exercise group demonstrated improved two-minute walk (p < 0.05), chair sit tests (p < 0.05), and results of the SFT. The online video resistance training may help to increase cognitive function and fitness in older adults.
Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive standard gauze dressing with no negative pressure application.
The utility model relates to a medicine plaster appliance for preventing and curing tinea pedis, in particular to a tinea pedis clamp. Comprises a dry cotton ellipsoid containing a proper amount of medicine, a flexible linear fixed core penetrates through the center of the long axis of the ellipsoid, and rectangular fixed adhesive tapes are respectively arranged outside the centers of two ends of the long axis. The tinea pedis clamp can provide a method for treating the tinea pedis between toes, which is based on physical transfer control, combines the physical transfer control with the medical sterilization and disinfection to ensure that the environment between the toes is improved and the growth of fungi is inhibited. Furthermore, the dry cotton ball containing the medicine to be prepared is clamped at the root part between the toes to be used as a fulcrum, the distance between the toes is expanded, the skin between the affected toes is fully separated and ventilated, and the dry cotton ball containing the acidic substance continuously absorbs moisture and is killed in a targeted way, so that the tinea pedis between the toes can be promoted to be cured as soon as possible. Compared with the prior art, the method has the advantages of strong physical control and prevention combination, stable clamping and fixation of the absorbent cotton balls, difficulty in slipping, convenience in operation, and environmental friendliness. Can also be used as a daily prevention and treatment article for the life of people susceptible to tinea pedis and travel.